These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 15072889

  • 1. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population.
    Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y.
    Urology; 2004 Apr; 63(4):727-31. PubMed ID: 15072889
    [Abstract] [Full Text] [Related]

  • 2. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg RE, Pollack A, Hanks GE, Watkins-Bruner D.
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [Abstract] [Full Text] [Related]

  • 3. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
    Kim HS, Jeon SS, Choi JD, Kim W, Han DH, Jeong BC, Seo SI, Lee KS, Lee SW, Lee HM, Choi HY.
    Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
    [Abstract] [Full Text] [Related]

  • 4. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK, Hong SK, Byun SS, Lee SE.
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [Abstract] [Full Text] [Related]

  • 5. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study.
    Kaplan SA, Ghafar MA, Volpe MA, Lam JS, Fromer D, Te AE.
    Urology; 2002 Sep; 60(3):464-8. PubMed ID: 12350485
    [Abstract] [Full Text] [Related]

  • 6. Low AUA symptom score independently predicts positive prostate needle biopsy: results from a racially diverse series of 411 patients.
    Porter CR, Kim J.
    Urology; 2004 Jan; 63(1):90-4. PubMed ID: 14751356
    [Abstract] [Full Text] [Related]

  • 7. Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels.
    Arai Y, Maeda H, Ishitoya S, Okubo K, Okada T, Aoki Y.
    J Urol; 1997 Sep; 158(3 Pt 1):861-4. PubMed ID: 9258099
    [Abstract] [Full Text] [Related]

  • 8. Detection of prostate cancer at low and intermediate serum prostate-specific antigen levels in a country with a low incidence of prostate cancer.
    Lee SE, Byun SS, Park HK, Shim HB, Ku JH.
    Jpn J Clin Oncol; 2006 Jun; 36(6):376-80. PubMed ID: 16735369
    [Abstract] [Full Text] [Related]

  • 9. Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population.
    He D, Wang M, Chen X, Gao Z, He H, Zhau HE, Wang W, Chung LW, Nan X.
    Urology; 2004 Apr; 63(4):722-6. PubMed ID: 15072888
    [Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
    Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ.
    Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
    [Abstract] [Full Text] [Related]

  • 11. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
    Freedland SJ, Mangold LA, Epstein JI, Partin AW.
    Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
    [Abstract] [Full Text] [Related]

  • 12. Influence of prostate volume in the detection of prostate cancer.
    Basillote JB, Armenakas NA, Hochberg DA, Fracchia JA.
    Urology; 2003 Jan; 61(1):167-71. PubMed ID: 12559290
    [Abstract] [Full Text] [Related]

  • 13. Predicting the extent of prostate cancer using the combination of systematic biopsy and serum prostate-specific antigen in Japanese men.
    Gohji K, Okamoto M, Takenaka A, Nomi M, Fujii A.
    BJU Int; 1999 Jan; 83(1):39-42. PubMed ID: 10233449
    [Abstract] [Full Text] [Related]

  • 14. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
    Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC, Dorey F, Terris MK, SEARCH Database Study Group.
    Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
    [Abstract] [Full Text] [Related]

  • 15. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.
    Eur Urol; 1999 Apr; 35(5-6):523-38. PubMed ID: 10325519
    [Abstract] [Full Text] [Related]

  • 16. [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy].
    Di Donna A, Bazzocchi M, Guerra UP, Bendini M, De Biasi F, Caminiti F, Delendi M.
    Radiol Med; 1993 Apr; 85(1-2):84-9. PubMed ID: 7683136
    [Abstract] [Full Text] [Related]

  • 17. Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity.
    Ku JH, Ahn JO, Lee CH, Lee NK, Park YH, Byun SS, Kwak C, Lee SE.
    Urology; 2002 Sep; 60(3):475-9. PubMed ID: 12350489
    [Abstract] [Full Text] [Related]

  • 18. Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels.
    Schmid HP, Ravery V, Billebaud T, Toublanc M, Boccon-Gibod LA, Hermieu JF, Delmas V, Boccon-Gibod L.
    Urology; 1996 May; 47(5):699-703. PubMed ID: 8650868
    [Abstract] [Full Text] [Related]

  • 19. Prostate cancer detection at low prostate specific antigen.
    Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R.
    J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
    [Abstract] [Full Text] [Related]

  • 20. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, Tomita K, Umekawa T, Uemura H, Miki T.
    BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.